🔄
PROTOCOL CHANGE — August 17, 2026
BPC-157 product switch, effective August 18, 2026. The Apeiron Elements BPC-157 Prime w/CurcuPrime capsule is being discontinued after its final dose on Aug 17; ProHealth Longevity's Pure BPC-157 (500 mcg, single-ingredient BPC-157 arginate salt) starts the following day, on the same 4-weeks-on/2-weeks-off cycling schedule already in use — Cycle 4 (running Aug 11–Sep 7) continues under the new product without interruption. The Apeiron card below is left in place and marked DISCONTINUED for the historical record; ProHealth's Pure BPC-157 is graded independently right after it, including what's gained (Triple Lab Tested third-party verification, arginate-salt stability) and what's lost in the switch (the CurcuPrime curcumin co-formulation). See the updated Summary Scorecard and Daily Dosing Schedule below. Prior revision (Aug 16, 2026, Mitopure/Urolithin A) carries forward unchanged.
Grading Framework
Brand / Quality
Manufacturing standards (GMP, NSF, TGA), third-party testing, purity, heavy metal screening, label accuracy.
Bioavailability / Form
Is the active compound in the most absorbable form? Chelated minerals > oxide forms.
Clinical Evidence
Depth of human RCTs, meta-analyses, and mechanistic studies.
A
Berberine RE-GRADED AUG 2026
Thorne · Fullscript · 2 caps/day · $40.49/mo
Overall
Grade
Grade
Why You're Taking It
Primary (was glucose, now lipids): LDL/ApoB reduction. Berberine downregulates PCSK9 and upregulates hepatic LDL receptor expression — a mechanism fully independent of HMG-CoA reductase, so it stacks additively with red yeast rice rather than duplicating it. With the plateau now broken (LDL 125 → 108, ApoB 104 → 93) this is the pathway that visibly delivered.
Secondary: Triglyceride reduction. Berberine has consistent meta-analytic TG-lowering data — newly relevant given the Jul'26 reversal to 144–153 mg/dL. This is now berberine's most urgent job, not its glucose effect.
Tertiary: Gut microbiome modulation toward butyrate producers — mechanistically complementary to the Phase 4 repletion stack.
Demoted: fasting glucose control. Glucose is 87 mg/dL, insulin 6.0, A1c 5.1 — all best-ever. Berberine is no longer load-bearing here (see the CGM finding below).
Secondary: Triglyceride reduction. Berberine has consistent meta-analytic TG-lowering data — newly relevant given the Jul'26 reversal to 144–153 mg/dL. This is now berberine's most urgent job, not its glucose effect.
Tertiary: Gut microbiome modulation toward butyrate producers — mechanistically complementary to the Phase 4 repletion stack.
Demoted: fasting glucose control. Glucose is 87 mg/dL, insulin 6.0, A1c 5.1 — all best-ever. Berberine is no longer load-bearing here (see the CGM finding below).
Sub-Grades
Brand
9.5
Bioavail
8.5
Evidence
9.5
Relevance
9.4
Evidence Depth
Landmark: Yin et al. (2008) — berberine matched metformin for A1C reduction (-0.9%) in a 3-month RCT. Zhang et al. (2015) meta-analysis of 27 RCTs confirmed significant reductions in fasting glucose (-0.56 mmol/L), HOMA-IR, triglycerides, and LDL. Dong et al. (2012) showed 23.8% LDL reduction via LDLR upregulation through the PCSK9 pathway — a completely different mechanism than statins or red yeast rice.
Brand Quality Assessment
Thorne Berberine-500 is pharmaceutical-grade. Thorne is one of only ~5 supplement companies with TGA (Australian Therapeutic Goods) certification, NSF for Sport certification, and GMP compliance. They perform 4+ rounds of testing on every raw material. The berberine is sourced as berberine HCl, the most studied and bioavailable salt form. No fillers, no flow agents that impair absorption. The only knock is that berberine's inherent oral bioavailability is low (~5%) due to intestinal P-glycoprotein efflux — but this is a molecule-level limitation, not a brand limitation. Thorne is the best you can get for standard berberine.
⚠️ Aug 2026 Re-Grade — Role Reassigned, Not Downgraded
The glucose job is finished. The "~104 fasting glucose regression" this card was built around was a point-in-time outlier — Jul 27 came back at 87 mg/dL with insulin at 6.0, both best-ever. And the 15-day Stelo CGM captured the Jul 14–27 washout as a natural experiment: daily mean glucose fell throughout it (~98 → ~91 → ~85 → ~82), overall mean 89.7, TIR 97.6%. Control improved without berberine. At this stage of metabolic recovery, berberine is not the load-bearing glucose lever.
But the same washout may explain the triglyceride finding — and that changes the verdict.
Berberine Reset 1 ran Jul 14–27. Both lab draws fell inside it: Jul 20 = day 7 off, Jul 27 = day 14 off, the final day before resuming. There is no on-cycle triglyceride measurement anywhere in this lab batch.
Four things support the withdrawal hypothesis:
• Direction across the two draws. TG went 144 → 153 from day 7 to day 14 — rising as the washout deepened. Random variation or a diet shift wouldn't be expected to trend in the direction the pharmacology predicts.
• Mechanism fits. Berberine's AMPK activation suppresses hepatic lipogenesis and VLDL output. Withdraw it and hepatic TG export rises. Meta-analytic TG effect is roughly 25–45 mg/dL, which covers a large share of the ~65 mg/dL gap from the Mar'26 reading of 85.
• Pharmacokinetics fit. Berberine has low bioavailability and a short half-life; its metabolic effects don't persist for two weeks after cessation.
• LDL stayed excellent. LDL-C came in at 108 — best-ever — on the same draw (103 on the Jul 20 basic panel five days earlier, both well below the prior 125 plateau). That looks contradictory until you notice red yeast rice carries the LDL load independently via HMG-CoA inhibition, while nothing else in the stack is dedicated to triglycerides except EPA. So a berberine withdrawal should surface preferentially in TG and leave LDL buffered. It did exactly that.
What this does NOT settle: the NMR particle findings (LDL-P 1453, small LDL 298, large HDL low). CETP exchange is rapid, but building an established small-dense-LDL profile from 14 days of elevated TG is on the fast end of plausible. If the particle profile reflects a longer-running TG elevation than the washout can account for, then withdrawal is only part of the story. Unresolved — and it's the reason the diet question stays open rather than being dismissed.
Grade impact: if this hypothesis holds, berberine is doing more work than the old card credited — just on lipids rather than glucose. Relevance revised to 9.4 (not the 8.8 initially assigned when only the glucose demotion was in view). Grade held at A pending confirmation; returns to A+ if the on-cycle retest confirms TG drops back.
Action: retest triglycerides mid-ON-cycle (berberine resumed Jul 28; Cycle 2 runs through Sep 21, so draw somewhere in late Aug–mid Sep). A cheap standalone lipid panel answers it. If TG returns to ~85, this was a sampling artifact and no aggressive intervention is warranted. If TG is still ~145 on-cycle, the withdrawal explanation is wrong and the dietary investigation becomes urgent.
Two durable protocol lessons: (1) standardize draw timing to a fixed point in the berberine cycle — otherwise every future lipid panel is confounded by which side of the cycle it landed on, and the longitudinal series becomes uninterpretable; (2) worth asking whether a 2-week washout that produces a ~65 mg/dL TG excursion is a good trade for AMPK resensitization, or whether a shorter reset would preserve the benefit. Raise with Dr. Nguyen — not a unilateral change.
But the same washout may explain the triglyceride finding — and that changes the verdict.
Berberine Reset 1 ran Jul 14–27. Both lab draws fell inside it: Jul 20 = day 7 off, Jul 27 = day 14 off, the final day before resuming. There is no on-cycle triglyceride measurement anywhere in this lab batch.
Four things support the withdrawal hypothesis:
• Direction across the two draws. TG went 144 → 153 from day 7 to day 14 — rising as the washout deepened. Random variation or a diet shift wouldn't be expected to trend in the direction the pharmacology predicts.
• Mechanism fits. Berberine's AMPK activation suppresses hepatic lipogenesis and VLDL output. Withdraw it and hepatic TG export rises. Meta-analytic TG effect is roughly 25–45 mg/dL, which covers a large share of the ~65 mg/dL gap from the Mar'26 reading of 85.
• Pharmacokinetics fit. Berberine has low bioavailability and a short half-life; its metabolic effects don't persist for two weeks after cessation.
• LDL stayed excellent. LDL-C came in at 108 — best-ever — on the same draw (103 on the Jul 20 basic panel five days earlier, both well below the prior 125 plateau). That looks contradictory until you notice red yeast rice carries the LDL load independently via HMG-CoA inhibition, while nothing else in the stack is dedicated to triglycerides except EPA. So a berberine withdrawal should surface preferentially in TG and leave LDL buffered. It did exactly that.
What this does NOT settle: the NMR particle findings (LDL-P 1453, small LDL 298, large HDL low). CETP exchange is rapid, but building an established small-dense-LDL profile from 14 days of elevated TG is on the fast end of plausible. If the particle profile reflects a longer-running TG elevation than the washout can account for, then withdrawal is only part of the story. Unresolved — and it's the reason the diet question stays open rather than being dismissed.
Grade impact: if this hypothesis holds, berberine is doing more work than the old card credited — just on lipids rather than glucose. Relevance revised to 9.4 (not the 8.8 initially assigned when only the glucose demotion was in view). Grade held at A pending confirmation; returns to A+ if the on-cycle retest confirms TG drops back.
Action: retest triglycerides mid-ON-cycle (berberine resumed Jul 28; Cycle 2 runs through Sep 21, so draw somewhere in late Aug–mid Sep). A cheap standalone lipid panel answers it. If TG returns to ~85, this was a sampling artifact and no aggressive intervention is warranted. If TG is still ~145 on-cycle, the withdrawal explanation is wrong and the dietary investigation becomes urgent.
Two durable protocol lessons: (1) standardize draw timing to a fixed point in the berberine cycle — otherwise every future lipid panel is confounded by which side of the cycle it landed on, and the longitudinal series becomes uninterpretable; (2) worth asking whether a 2-week washout that produces a ~65 mg/dL TG excursion is a good trade for AMPK resensitization, or whether a shorter reset would preserve the benefit. Raise with Dr. Nguyen — not a unilateral change.
A
Red Yeast Rice
Thorne · Fullscript · 1 cap/day · $12.82/mo
Overall
Grade
Grade
Why You're Taking It
Primary: LDL and ApoB reduction without statins. Red yeast rice contains monacolin K, which is chemically identical to lovastatin. It inhibits HMG-CoA reductase — the rate-limiting enzyme in hepatic cholesterol synthesis.
✅ Verdict returned (Jul 2026 labs): the plateau this card was written to break is broken. LDL 125 → 108 mg/dL. ApoB 104 → 93 mg/dL, now −33% from the 139 first measured in Jan'25. Total cholesterol 198 → 190. This is the single clearest supplement-attributable win in the stack — statin-class LDL movement achieved without a statin, in a patient carrying APOE e3/e4, the genotype that made the plateau stubborn in the first place.
Strategic context: Combined with berberine (LDLR upregulation via PCSK9) and omega-3s (triglyceride/VLDL clearance), you're hitting lipid metabolism from three independent pathways. This multi-vector approach is how functional medicine achieves statin-level lipid changes without the drug — and it now has your own longitudinal data behind it, not just the literature.
Remaining work: ApoB at 93 is improved but still above the <80 mg/dL optimal target, and the NMR panel added new detail the old lipid panel couldn't see (LDL-P 1453, small LDL 298). Continue at current dose — do not taper on the strength of one good panel.
✅ Verdict returned (Jul 2026 labs): the plateau this card was written to break is broken. LDL 125 → 108 mg/dL. ApoB 104 → 93 mg/dL, now −33% from the 139 first measured in Jan'25. Total cholesterol 198 → 190. This is the single clearest supplement-attributable win in the stack — statin-class LDL movement achieved without a statin, in a patient carrying APOE e3/e4, the genotype that made the plateau stubborn in the first place.
Strategic context: Combined with berberine (LDLR upregulation via PCSK9) and omega-3s (triglyceride/VLDL clearance), you're hitting lipid metabolism from three independent pathways. This multi-vector approach is how functional medicine achieves statin-level lipid changes without the drug — and it now has your own longitudinal data behind it, not just the literature.
Remaining work: ApoB at 93 is improved but still above the <80 mg/dL optimal target, and the NMR panel added new detail the old lipid panel couldn't see (LDL-P 1453, small LDL 298). Continue at current dose — do not taper on the strength of one good panel.
Sub-Grades
Brand
9.5
Bioavail
8.8
Evidence
9.2
Relevance
9.7
Evidence Depth
Landmark: The Chinese Coronary Secondary Prevention Study (CCSPS, n=4,870) demonstrated 45% reduction in cardiovascular events over 4.5 years with Xuezhikang (standardized RYR). Lu et al. (2022) meta-analysis of 53 RCTs showed average LDL reduction of 1.02 mmol/L (~39 mg/dL). One caveat: monacolin K content varies wildly between brands — Thorne standardizes theirs, which is critical.
Brand Quality Assessment
Thorne's red yeast rice is standardized for monacolin K content — this is the single most important quality metric. Many RYR products on the market contain negligible monacolin K, or worse, contain citrinin (a nephrotoxic mycotoxin produced during fermentation). Thorne tests for and certifies citrinin-free status. They also standardize the active compound so you're getting a consistent therapeutic dose. This matters because generic RYR products have been shown to vary by up to 100x in monacolin K content between brands. At 1 cap/day, confirm the monacolin K content on your label to ensure you're in the 3-10mg therapeutic range.
A+
Methyl-Guard Plus
Thorne · Fullscript · 3 caps/day · $56.69/mo
Overall
Grade
Grade
Why You're Taking It
Primary: This is the single most genetically-targeted supplement in your stack. You carry COMT G472A homozygous (enzyme at 0-10%), MTHFR A1298C heterozygous (~40% reduced), and MTRR A66G heterozygous (~40% reduced). Methyl-Guard Plus provides the exact cofactors your impaired methylation cycle needs:
• 5-MTHF (methylfolate) — bypasses your MTHFR A1298C bottleneck entirely. Your body can't efficiently convert folic acid to active folate; this delivers it pre-converted.
• Methylcobalamin (B12) — the active B12 form. Your MTRR mutation impairs B12 recycling; this ensures adequate substrate despite the enzyme deficit. Critically, this is NOT cyanocobalamin.
• Pyridoxal 5'-Phosphate (P5P/B6) — active B6 form, cofactor for 100+ enzymatic reactions including homocysteine clearance.
• Riboflavin 5'-Phosphate (active B2) — cofactor for MTHFR enzyme itself. Even with your mutation, providing activated riboflavin optimizes whatever function remains.
• Betaine (TMG) — alternative methyl donor pathway (BHMT), providing a backup methylation route that bypasses MTHFR entirely.
Secondary: Homocysteine management. Your baseline was 10.3 µmol/L — elevated. Methyl-Guard Plus attacks homocysteine through all three clearance pathways simultaneously (remethylation via MTHFR, remethylation via BHMT/betaine, and transsulfuration via B6).
✅ Aug 2026 — objectively confirmed working. Homocysteine sits at 8.2 µmol/L, inside the established 7–10 fluctuation band, down from the 10.3 baseline. More importantly, MMA came back at 62 nmol/L (from 76–81) — MMA is the functional, tissue-level B12 marker and it is unambiguously improving. That validates the methylcobalamin-over-cyanocobalamin choice for your MTRR heterozygosity with a direct measurement rather than an inference. No change: continue at current dose. This is the one supplement in the stack with a genetic indication that will never expire.
• 5-MTHF (methylfolate) — bypasses your MTHFR A1298C bottleneck entirely. Your body can't efficiently convert folic acid to active folate; this delivers it pre-converted.
• Methylcobalamin (B12) — the active B12 form. Your MTRR mutation impairs B12 recycling; this ensures adequate substrate despite the enzyme deficit. Critically, this is NOT cyanocobalamin.
• Pyridoxal 5'-Phosphate (P5P/B6) — active B6 form, cofactor for 100+ enzymatic reactions including homocysteine clearance.
• Riboflavin 5'-Phosphate (active B2) — cofactor for MTHFR enzyme itself. Even with your mutation, providing activated riboflavin optimizes whatever function remains.
• Betaine (TMG) — alternative methyl donor pathway (BHMT), providing a backup methylation route that bypasses MTHFR entirely.
Secondary: Homocysteine management. Your baseline was 10.3 µmol/L — elevated. Methyl-Guard Plus attacks homocysteine through all three clearance pathways simultaneously (remethylation via MTHFR, remethylation via BHMT/betaine, and transsulfuration via B6).
✅ Aug 2026 — objectively confirmed working. Homocysteine sits at 8.2 µmol/L, inside the established 7–10 fluctuation band, down from the 10.3 baseline. More importantly, MMA came back at 62 nmol/L (from 76–81) — MMA is the functional, tissue-level B12 marker and it is unambiguously improving. That validates the methylcobalamin-over-cyanocobalamin choice for your MTRR heterozygosity with a direct measurement rather than an inference. No change: continue at current dose. This is the one supplement in the stack with a genetic indication that will never expire.
Sub-Grades
Brand
9.7
Bioavail
9.8
Evidence
9.2
Relevance
10.0
Evidence Depth
The evidence base is individual-ingredient deep: 5-MTHF vs folic acid has been validated in multiple RCTs for MTHFR carriers (Prinz-Langenohl, 2009). Methylcobalamin's superiority over cyanocobalamin for MTRR carriers is well-established biochemically. The combination product approach for methylation support is the standard of care in functional medicine for compound heterozygous/homozygous MTHFR+MTRR profiles. Homocysteine reduction of 25-30% is typical with this formulation in genetically-indicated patients.
Brand Quality Assessment
This is Thorne's flagship methylation product and it's formulated specifically for MTHFR/MTRR carriers — it is one of the most precisely targeted B-complex products on the market. Every form is the activated/coenzymated version (5-MTHF, methylcobalamin, P5P, R5P). No folic acid. No cyanocobalamin. No pyridoxine HCl. This matters enormously for your genetics — your MTRR mutation means you can't efficiently recycle B12, so giving you the pre-activated forms bypasses the bottleneck. Thorne's 5-MTHF is Quatrefolic (glucosamine salt), the most stable and bioavailable methylfolate patent. This is the correct product for your genome. Non-negotiable in your stack.
A+
Super EPA Pro
Thorne · Fullscript · 3 caps/day · $84.59/mo
Overall
Grade
Grade
Why You're Taking It
Primary — now the #1 cardiovascular lever in the stack: Triglyceride and VLDL particle reduction. High-dose EPA/DHA reduces hepatic VLDL secretion and accelerates triglyceride clearance. Triglycerides fell 162 → 71 → 85 across 2024–Mar'26, but have reversed to 144–153 mg/dL on both the Jul 20 and Jul 27 draws — two independent panels five days apart, so this is confirmed, not assay noise.
Secondary: Systemic inflammation control. Your hs-CRP dropped from 2.46 to ~0.6 — omega-3s drive this by shifting eicosanoid production from pro-inflammatory (AA-derived) to pro-resolving (EPA/DHA-derived). SPMs (specialized pro-resolving mediators) are directly synthesized from EPA and DHA.
Tertiary: Membrane fluidity and cardiovascular protection. EPA/DHA physically incorporate into cell membranes, improving receptor signaling, endothelial function, and reducing platelet aggregation.
New this panel — omega-3 status was directly measured for the first time: Omega-3 Total 6.1%, Omega-6 Total 42.0%, Omega-6/3 ratio 6.9, AA/EPA ratio 5.6. All technically "in range," all above the optimal band (O6/3 <4, AA/EPA 1.5–3). This is objective evidence the current dose is adequate but not optimal — worth keeping an eye on alongside the triglyceride retest below.
Secondary: Systemic inflammation control. Your hs-CRP dropped from 2.46 to ~0.6 — omega-3s drive this by shifting eicosanoid production from pro-inflammatory (AA-derived) to pro-resolving (EPA/DHA-derived). SPMs (specialized pro-resolving mediators) are directly synthesized from EPA and DHA.
Tertiary: Membrane fluidity and cardiovascular protection. EPA/DHA physically incorporate into cell membranes, improving receptor signaling, endothelial function, and reducing platelet aggregation.
New this panel — omega-3 status was directly measured for the first time: Omega-3 Total 6.1%, Omega-6 Total 42.0%, Omega-6/3 ratio 6.9, AA/EPA ratio 5.6. All technically "in range," all above the optimal band (O6/3 <4, AA/EPA 1.5–3). This is objective evidence the current dose is adequate but not optimal — worth keeping an eye on alongside the triglyceride retest below.
Sub-Grades
Brand
9.7
Bioavail
9.2
Evidence
9.8
Relevance
10.0
Evidence Depth
Among the most studied supplements in existence. REDUCE-IT (2019, n=8,179) showed 25% relative reduction in cardiovascular events with high-dose EPA. Omega-3 meta-analyses consistently show triglyceride reduction of 20-30%, CRP reduction of 15-30%, and blood pressure reduction of 2-5 mmHg. The EPA:DHA ratio matters — Super EPA Pro is EPA-dominant, which aligns with the strongest cardiovascular evidence (REDUCE-IT was EPA-only).
Brand Quality Assessment
Thorne Super EPA Pro is one of the highest-concentration omega-3 products available without a prescription. Thorne's fish oil is IFOS 5-star certified (International Fish Oil Standards — the gold standard), molecularly distilled to remove mercury, PCBs, and dioxins. Each gelcap delivers a verified 650 mg EPA + 100 mg DHA, sourced solely from anchovies via supercritical CO2 extraction. This is legitimately the top tier of fish oil supplements.
⚠️ Correction, Aug 2, 2026 — prior versions of this report were wrong about the form. This card previously stated Super EPA Pro uses re-esterified triglyceride (rTG) form with "70% greater bioavailability than ethyl ester." That is incorrect. The label reads "Eicosapentaenoic Acid Ethyl Ester" and "Docosahexaenoic Acid Ethyl Ester" — Super EPA Pro is an ethyl ester (EE) product. The rTG description appears to have been carried over from Thorne's standard Super EPA line.
Why this matters practically, and why it isn't a reason to switch products:
• Take it with the fattiest meal of the day. EE-form omega-3 absorption is substantially more fat-dependent than rTG — taken on an empty stomach or with a low-fat meal, absorption drops sharply.
• The evidence base actually favors EE here. REDUCE-IT — the landmark trial cited above, and the strongest cardiovascular outcome data in the omega-3 literature — used icosapent ethyl, an ethyl ester. The form you are taking is the form that produced the outcome data most relevant to your risk profile.
• Net: the brand-quality grade stands (9.7), the bioavailability sub-grade is arguably a touch generous at 9.2 for an EE product, and the correct response is a timing adjustment, not a product change.
⚠️ Correction, Aug 2, 2026 — prior versions of this report were wrong about the form. This card previously stated Super EPA Pro uses re-esterified triglyceride (rTG) form with "70% greater bioavailability than ethyl ester." That is incorrect. The label reads "Eicosapentaenoic Acid Ethyl Ester" and "Docosahexaenoic Acid Ethyl Ester" — Super EPA Pro is an ethyl ester (EE) product. The rTG description appears to have been carried over from Thorne's standard Super EPA line.
Why this matters practically, and why it isn't a reason to switch products:
• Take it with the fattiest meal of the day. EE-form omega-3 absorption is substantially more fat-dependent than rTG — taken on an empty stomach or with a low-fat meal, absorption drops sharply.
• The evidence base actually favors EE here. REDUCE-IT — the landmark trial cited above, and the strongest cardiovascular outcome data in the omega-3 literature — used icosapent ethyl, an ethyl ester. The form you are taking is the form that produced the outcome data most relevant to your risk profile.
• Net: the brand-quality grade stands (9.7), the bioavailability sub-grade is arguably a touch generous at 9.2 for an EE product, and the correct response is a timing adjustment, not a product change.
A
Seed DS-01 Daily Synbiotic
Seed · Fullscript · 2 caps/day · $53.99/mo
Overall
Grade
Grade
Why You're Taking It
Primary: Gut barrier integrity and microbiome diversity maintenance after your completed 3-phase gut protocol. 24 clinically studied probiotic strains with a prebiotic outer capsule.
Secondary: Metabolic signaling via gut-liver axis — SCFA-producing strains improve insulin sensitivity.
Tertiary: Immune modulation; hs-CRP 0.6 reflects excellent systemic inflammation control, to which a healthy microbiome contributes.
Secondary: Metabolic signaling via gut-liver axis — SCFA-producing strains improve insulin sensitivity.
Tertiary: Immune modulation; hs-CRP 0.6 reflects excellent systemic inflammation control, to which a healthy microbiome contributes.
Sub-Grades
Brand
9.2
Bioavail
9.0
Evidence
8.2
Relevance
8.8
Brand Quality Assessment
Seed is a science-forward probiotic company with AFU-verified viability and nested-capsule delivery technology. Premium tier of probiotics; the 24-strain combination as a whole product needs more independent replication, hence A not A+.
A
NeuroCalm
Designs for Health · Fullscript · 2 caps/day · $53.99/mo
Overall
Grade
Grade
Why You're Taking It
Primary: Neurotransmitter balance for COMT homozygous profile — PharmaGABA, 5-HTP, phosphatidylserine, taurine, chamomile targeting inhibitory/calming pathways to counterbalance elevated catecholamines.
Secondary: Cortisol modulation via phosphatidylserine, important given daily training/sauna HPA stimulation.
Secondary: Cortisol modulation via phosphatidylserine, important given daily training/sauna HPA stimulation.
Sub-Grades
Brand
9.3
Bioavail
8.5
Evidence
7.8
Relevance
9.2
Brand Quality Assessment
Designs for Health is practitioner-only, GMP-certified, third-party tested; uses patented PharmaGABA rather than synthetic GABA. Same tier as Thorne/Metagenics.
A
Vitamin D3 5000 + K
Metagenics · Fullscript Bimonthly · 1 cap/day · $13.05/mo
Overall
Grade
Grade
Why You're Taking It
Primary: Corrected a critical baseline deficiency (17.1 ng/mL). D holding at 62 ng/mL, stable across four draws — correction complete and maintained, no dose change indicated.
K2 inclusion is critical: directs D3-mobilized calcium to bone (osteocalcin, matrix Gla-protein) rather than arteries — protective given elevated ApoB.
K2 inclusion is critical: directs D3-mobilized calcium to bone (osteocalcin, matrix Gla-protein) rather than arteries — protective given elevated ApoB.
Sub-Grades
Brand
9.2
Bioavail
9.0
Evidence
9.5
Relevance
9.5
Brand Quality Assessment
Metagenics GMP+ certified; cholecalciferol + MK-7 K2 in a lipid-base softgel. Best-value supplement in the stack relative to critical baseline need.
A
Magnesium Glycinate
Metagenics · Fullscript Bimonthly · 2 tabs/day · $15.30/mo
Overall
Grade
Grade
Why You're Taking It
Primary: COMT cofactor support — magnesium is a direct cofactor for the COMT enzyme (0-10% function).
Secondary: Recovery/nervous system — glycine is an inhibitory neurotransmitter supporting sleep, complementing NeuroCalm.
Tertiary: Insulin receptor tyrosine kinase cofactor.
Secondary: Recovery/nervous system — glycine is an inhibitory neurotransmitter supporting sleep, complementing NeuroCalm.
Tertiary: Insulin receptor tyrosine kinase cofactor.
Sub-Grades
Brand
9.2
Bioavail
9.0
Evidence
9.0
Relevance
9.5
Brand Quality Assessment
True chelated bisglycinate form, tested for heavy metals. Excellent value.
A
Basic Nutrients 2/Day
Thorne · Fullscript · 2 caps/day · $62.09/mo
Overall
Grade
Grade
Why You're Taking It
Primary: Micronutrient insurance on a low-carb/IF diet — trace minerals and fat-soluble vitamins.
⚠️ Jul 2026 — zinc coverage came up short. Serum zinc declined across five draws (74→72→69→70→63 mcg/dL) through the period this multi has run — a maintenance dose, not a repletion dose. Relevance dropped 9.2→8.4. See standalone Zinc recommendation.
No EGCG (unlike the prior BodyHealth multi) — critical for COMT homozygous status.
⚠️ Jul 2026 — zinc coverage came up short. Serum zinc declined across five draws (74→72→69→70→63 mcg/dL) through the period this multi has run — a maintenance dose, not a repletion dose. Relevance dropped 9.2→8.4. See standalone Zinc recommendation.
No EGCG (unlike the prior BodyHealth multi) — critical for COMT homozygous status.
Sub-Grades
Brand
9.7
Bioavail
9.3
Evidence
8.0
Relevance
8.4
Brand Quality Assessment
NSF Certified for Sport, TRAACS® chelated minerals, active B-vitamin forms. $14.58/mo cheaper than the prior multi with a quality upgrade.
B+
BPC-157 Prime w/CurcuPrime DISCONTINUED — AUG 17, 2026
Apeiron Elements · Manual Order · 1 cap/day (4 on/2 off cycling) · $35.00/mo
Overall
Grade
Grade
Why You're Taking It
Primary: Gut mucosal repair and systemic tissue healing — upregulates EGF/VEGF/FGF and angiogenesis.
Secondary: Musculoskeletal/tendon-ligament recovery.
CurcuPrime: NF-kB inhibition, complementary inflammatory modulation.
Secondary: Musculoskeletal/tendon-ligament recovery.
CurcuPrime: NF-kB inhibition, complementary inflammatory modulation.
Sub-Grades
Brand
8.0
Bioavail
7.2
Evidence
5.8
Relevance
8.5
Brand Quality Assessment
Zero large-scale human RCTs for oral BPC-157 exist yet — extensive animal data, strong mechanism, thin human evidence. Currently mid-reset (resumed Aug 11, Cycle 4).
Discontinued Aug 17, 2026 — retained here for the historical record. Replaced by ProHealth Longevity's Pure BPC-157 starting Aug 18, 2026 (see card below), on the same cycling schedule. This card's grade and sub-grades are frozen as of its last active day and no longer update.
Discontinued Aug 17, 2026 — retained here for the historical record. Replaced by ProHealth Longevity's Pure BPC-157 starting Aug 18, 2026 (see card below), on the same cycling schedule. This card's grade and sub-grades are frozen as of its last active day and no longer update.
B+
Pure BPC-157 NEW — STARTS AUG 18, 2026
ProHealth Longevity · Manual Order · 1 cap/day, 500 mcg (4 on/2 off cycling) · $59.98/mo
Overall
Grade
Grade
Why You're Taking It
Primary: Gut mucosal repair and systemic tissue healing — same BPC-157 mechanism as the discontinued Apeiron product (upregulates EGF/VEGF/FGF and angiogenesis). This is a product switch, not a mechanism change.
Secondary: Musculoskeletal/tendon-ligament recovery.
What's different: single-ingredient 500 mcg BPC-157 arginate salt capsule — no CurcuPrime curcumin co-formulation (see Brand Quality Assessment for what that trade-off means). Same 4-weeks-on/2-weeks-off cycling, same 1 cap/day dose. Starts Aug 18, 2026, continuing Apeiron's in-progress Cycle 4 (Aug 11–Sep 7) under the new product.
Secondary: Musculoskeletal/tendon-ligament recovery.
What's different: single-ingredient 500 mcg BPC-157 arginate salt capsule — no CurcuPrime curcumin co-formulation (see Brand Quality Assessment for what that trade-off means). Same 4-weeks-on/2-weeks-off cycling, same 1 cap/day dose. Starts Aug 18, 2026, continuing Apeiron's in-progress Cycle 4 (Aug 11–Sep 7) under the new product.
Sub-Grades
Brand
8.3
Bioavail
7.4
Evidence
5.8
Relevance
8.2
Brand Quality Assessment
ProHealth Longevity's Pure BPC-157 is a single-ingredient capsule (BPC-157 arginate salt, 500 mcg) manufactured in an FDA-registered, GMP-certified facility. It's marketed as "Triple Lab Tested" — independent third-party verification of potency plus screening for heavy metals, microbial pathogens, and residual solvents, with lab results published — a brand-quality tier comparable to Apeiron. The arginate salt form is positioned for greater gastrointestinal stability than a plain acetate peptide, though — same caveat as the outgoing product — there is no human pharmacokinetic data confirming oral BPC-157 survives digestion intact regardless of salt form; the therapeutic case still rests on preclinical/animal mechanism data and the peptide's apparent tolerability, not human RCTs. Evidence sub-grade (5.8) is carried unchanged from the Apeiron card for that reason — the switch doesn't change what's actually been studied in humans.
What's lost in the switch: the CurcuPrime curcumin co-formulation (NF-kB inhibition, a complementary anti-inflammatory mechanism) that shipped inside the Apeiron capsule is not present in this single-ingredient product. Relevance is trimmed slightly (8.5 → 8.2) to reflect that narrower scope. No standalone curcumin/anti-inflammatory replacement is being added for this — noted here for the record, not as an open action item.
What's lost in the switch: the CurcuPrime curcumin co-formulation (NF-kB inhibition, a complementary anti-inflammatory mechanism) that shipped inside the Apeiron capsule is not present in this single-ingredient product. Relevance is trimmed slightly (8.5 → 8.2) to reflect that narrower scope. No standalone curcumin/anti-inflammatory replacement is being added for this — noted here for the record, not as an open action item.
A
Super Ubiquinol CoQ10 with PQQ
Life Extension · Fullscript · 1 softgel/day · ~$30.38/mo
Overall
Grade
Grade
Why You're Taking It
Primary: CoQ10 repletion — mandatory while on red yeast rice, which depletes endogenous CoQ10 via mevalonate-pathway inhibition.
Secondary: Mitochondrial biogenesis via PQQ (10mg here + 10mg standalone = 20mg total), activating PGC-1α.
Tertiary: Shilajit fulvic acid complex amplifies CoQ10 ATP output 27-56% in published research.
Secondary: Mitochondrial biogenesis via PQQ (10mg here + 10mg standalone = 20mg total), activating PGC-1α.
Tertiary: Shilajit fulvic acid complex amplifies CoQ10 ATP output 27-56% in published research.
Sub-Grades
Brand
9.2
Bioavail
9.4
Evidence
9.2
Relevance
9.5
Brand Quality Assessment
Kaneka™ Ubiquinol, ConsumerLab #1 rated 7 consecutive years, NSF GMP certified. Replaced CellCore MitoActive (B grade) at lower cost with superior sourcing.
A-
PQQ Caps 10 mg TOP-UP
Life Extension · Fullscript · 1 cap/day · ~$6.75/mo
Overall
Grade
Grade
Why You're Taking It
Primary: Completes the 20mg/day PQQ clinical dose used in mitochondrial biogenesis research — the CoQ10+PQQ softgel alone only supplies 10mg.
Sub-Grades
Brand
9.2
Bioavail
8.5
Evidence
7.8
Relevance
9.0
Brand Quality Assessment
BioPQQ®, NSF GMP certified. Most cost-efficient supplement in the stack relative to therapeutic value.
A
Cellular Longevity PRO — Mitopure (Urolithin A) 1000mg NEW · AUG 16 2026
Timeline (Amazentis) · Fullscript · 1000mg/day (2 caps) · ~$110/mo (estimate — confirm at checkout)
Overall
Grade
Grade
Why You're Taking It
Primary: Mitophagy activation — Urolithin A is the best-characterized natural compound that directly triggers clearance of damaged mitochondria and stimulates biogenesis of new ones, independent of the PGC-1α pathway that PQQ already drives in this stack. This is a proactive longevity addition, not a lab-flag response: it slots alongside the existing CoQ10+PQQ mitochondrial pair as a third, mechanistically distinct lever (PQQ = biogenesis signal, CoQ10 = electron-transport-chain substrate, Urolithin A = damaged-mitochondria clearance).
Secondary: Muscle strength/endurance support. The 2022 Cell Reports Medicine dose-response trial (500mg vs 1,000mg Mitopure) showed measurable gains in muscle strength and endurance markers at the doses used here — directly relevant to preserving muscle mass, a standing constraint of this protocol.
Tertiary: Immune-aging support. A November 2025 RCT (also using 1,000mg Mitopure) showed favorable shifts in naive CD8+ T cells, NK cell activity, and inflammatory markers — an emerging but less-replicated finding, appropriately framed as exploratory rather than established.
Dose rationale: 1,000mg/day (not 500mg) was chosen specifically because both the immune-aging trial and the strongest metabolic/inflammatory arm of the 2022 trial used 1,000mg — matching the dose to the evidence actually being relied on, rather than defaulting to the lower/cheaper option.
Secondary: Muscle strength/endurance support. The 2022 Cell Reports Medicine dose-response trial (500mg vs 1,000mg Mitopure) showed measurable gains in muscle strength and endurance markers at the doses used here — directly relevant to preserving muscle mass, a standing constraint of this protocol.
Tertiary: Immune-aging support. A November 2025 RCT (also using 1,000mg Mitopure) showed favorable shifts in naive CD8+ T cells, NK cell activity, and inflammatory markers — an emerging but less-replicated finding, appropriately framed as exploratory rather than established.
Dose rationale: 1,000mg/day (not 500mg) was chosen specifically because both the immune-aging trial and the strongest metabolic/inflammatory arm of the 2022 trial used 1,000mg — matching the dose to the evidence actually being relied on, rather than defaulting to the lower/cheaper option.
Sub-Grades
Brand
9.5
Bioavail
8.8
Evidence
7.4
Relevance
8.2
Evidence Depth
Same intellectual-honesty framing as BPC-157 and the Phase 4 gut additions in this stack: the mitophagy mechanism itself is well-established preclinical biology (Ryu et al., 2016, originally published in Nature Medicine), and the two human RCTs that exist are both well-conducted and both used this exact branded ingredient — but it's still a two-trial evidence base for a novel compound, not the 50+ meta-analysis depth behind creatine or omega-3s elsewhere in this stack. Evidence sits at 7.4 to reflect that honestly; Relevance at 8.2 because this is a proactive longevity bet rather than a response to a confirmed deficit, unlike most of the rest of the protocol.
Brand Quality Assessment
Timeline is Amazentis's own consumer brand — Amazentis is the Swiss (EPFL-spinout) biotech that holds the Mitopure patents and ran essentially all of the human trials behind urolithin A. Unlike most ingredients in this stack, urolithin A is not a commodity molecule: generic "urolithin A" listings are frequently extracted from pomegranate husk via a different process, yielding a different isomer mix with far less — or no — supporting human data. Timeline's own 2023 third-party testing of two competing Amazon "urolithin A" products found zero detectable urolithin A in either, despite label claims. Buying the Mitopure-branded product through Fullscript (the same practitioner-verification channel already used for Thorne, Life Extension, Designs for Health, and Microbiome Labs) avoids that risk entirely. Full sourcing analysis on file: claude/Mitopure_Buying_Guide_Aug2026.html and claude/Mitopure_Urolithin_A_Deep_Dive_Aug2026.html.
📋 Sequencing note
Taken fasted at 7:30 AM, alongside the other morning capsules (BPC-157, Lion's Mane, CoQ10+PQQ, D3+K2). Unlike Super EPA Pro and Basic Nutrients, Urolithin A absorption is not meaningfully fat-dependent, so there's no reason to hold it for the 11 AM meal block — it's grouped with the fasted-capsule tier instead. No interaction with existing CoQ10/PQQ dosing; this runs as its own independent 90-day cycle rather than being stacked into an evaluation window with any other new addition. Retest: no specific biomarker directly tracks mitophagy activity, so this is being added and continued on trial-evidence grounds rather than a personal lab target — reassess at 90 days on subjective recovery/training tolerance and at the next full panel for any unexpected interaction.
B+
Lion's Mane
Real Mushrooms · Manual Order · 2 caps/day · $34.98/mo
Overall
Grade
Grade
Why You're Taking It
Primary: NGF stimulation and neuroplasticity via hericenones/erinacines.
Secondary: Structural neuron support alongside NeuroCalm's software-level COMT management.
Secondary: Structural neuron support alongside NeuroCalm's software-level COMT management.
Sub-Grades
Brand
9.0
Bioavail
8.5
Evidence
6.8
Relevance
8.0
Brand Quality Assessment
Real Mushrooms — 100% fruiting body, verified beta-glucan content, no grain fillers. Reference standard for mushroom supplements.
A
FiberMend
Thorne · Fullscript Monthly · Powder · $41.39/mo
Overall
Grade
Grade
Why You're Taking It
Primary: Prebiotic fiber (Sunfiber®-brand PHGG base) for microbiome support.
Secondary — non-redundant job: Bile acid binding for LDL reduction, additive to red yeast rice and berberine. ✅ Verdict returned: LDL 125→108, ApoB 104→93. Keep, unchanged.
Overlaps with standalone Sunfiber on the PHGG ingredient (~12g/day combined) but each has a distinct, confirmed job — FiberMend for lipids, Sunfiber for F. prausnitzii gut restoration. Both continue indefinitely.
Secondary — non-redundant job: Bile acid binding for LDL reduction, additive to red yeast rice and berberine. ✅ Verdict returned: LDL 125→108, ApoB 104→93. Keep, unchanged.
Overlaps with standalone Sunfiber on the PHGG ingredient (~12g/day combined) but each has a distinct, confirmed job — FiberMend for lipids, Sunfiber for F. prausnitzii gut restoration. Both continue indefinitely.
Sub-Grades
Brand
9.5
Bioavail
8.8
Evidence
9.0
Relevance
9.0
Brand Quality Assessment
Sunfiber® PHGG base, best GI tolerability of prebiotic fibers. Clean formulation.
A+
Creatine
Thorne · Fullscript · Powder · $12.75/mo
Overall
Grade
Grade
Why You're Taking It
Primary: Strength performance and body composition through the body-recomposition phase.
Secondary: Neuroprotection/cognitive function via brain ATP substrate.
Tertiary: Methylation sparing — creatine synthesis consumes ~40% of SAMe-derived methyl groups; supplementing directly frees methyl groups for other reactions, relevant given MTHFR/COMT load.
Secondary: Neuroprotection/cognitive function via brain ATP substrate.
Tertiary: Methylation sparing — creatine synthesis consumes ~40% of SAMe-derived methyl groups; supplementing directly frees methyl groups for other reactions, relevant given MTHFR/COMT load.
Sub-Grades
Brand
9.5
Bioavail
9.5
Evidence
9.9
Relevance
9.6
Brand Quality Assessment
Creapure®, 99.99% purity, HPLC-verified, NSF for Sport. Best value-for-evidence supplement in the entire stack.
A
LMNT Electrolytes
LMNT · Direct / Subscribe & Save · 1 stick/day · $39.00/mo
Overall
Grade
Grade
Why You're Taking It
Primary: Electrolyte replacement for IF + low-carb + daily sauna + strength training.
Secondary: Performance/cognitive output; sodium supports adrenal function against COMT-driven catecholamine load.
Secondary: Performance/cognitive output; sodium supports adrenal function against COMT-driven catecholamine load.
Sub-Grades
Brand
9.0
Bioavail
9.2
Evidence
8.5
Relevance
9.3
Brand Quality Assessment
Clean formula (sodium chloride, magnesium malate, potassium chloride). Sodium-forward, purpose-built for the low-carb/keto athletic population.
🧬 New Additions — Phase 4 Microbiome Optimization Protocol
Trigger: June 2026 GI-MAP retest. Akkermansia muciniphila and Faecalibacterium prausnitzii both undetectable despite the earlier 3-phase gut protocol's success elsewhere (EPEC/EHEC cleared, calprotectin 0). Four additions selectively feed/restore the two missing species rather than run another antimicrobial round.
A
Akkermansia 500 PRO
Pendulum · Manual Order · 1 cap/day · $62.99/mo
Overall
Grade
Grade
Why You're Taking It
Primary: Direct repletion of Akkermansia muciniphila, confirmed undetectable on GI-MAP — a confirmed-zero repletion case, not a general-population guess.
Secondary: Metabolic support; the Jul CGM's steady glucose decline through the Phase 4 ramp is suggestive but not proof (correlation, not causation) — the 6-month GI-MAP retest is the real verification step.
Secondary: Metabolic support; the Jul CGM's steady glucose decline through the Phase 4 ramp is suggestive but not proof (correlation, not causation) — the 6-month GI-MAP retest is the real verification step.
Sub-Grades
Brand
8.8
Bioavail
8.0
Evidence
7.8
Relevance
9.8
Brand Quality Assessment
Most established commercial Akkermansia brand; 100M AFU delayed-release. Live-strain evidence is a tier behind the pasteurized-strain trial data, hence Evidence 7.8 despite near-maximal Relevance.
A
Sunfiber® (PHGG)
Tomorrow's Nutrition · Manual Order · 7g/day (full dose) · ~$32.22/mo
Overall
Grade
Grade
Why You're Taking It
Primary: Primary substrate for rebuilding F. prausnitzii, an obligate anaerobe with no commercial standalone probiotic — feeding it is the only lever.
Reached full 7g/day dose Jul 26. Overlaps with FiberMend's PHGG but serves a distinct, confirmed job (gut restoration vs. lipid binding).
Reached full 7g/day dose Jul 26. Overlaps with FiberMend's PHGG but serves a distinct, confirmed job (gut restoration vs. lipid binding).
Sub-Grades
Brand
8.5
Bioavail
9.0
Evidence
8.8
Relevance
9.6
Brand Quality Assessment
Same clinically-studied Sunfiber® raw material Thorne uses in FiberMend, sold standalone for precise titration.
B+
Tri-Butyrin Supreme
Designs for Health · Fullscript · 1 cap 2x/day · $44.09/mo
Overall
Grade
Grade
Why You're Taking It
Primary: Butyrate bridge — supplies the downstream metabolite F. prausnitzii would normally produce while the prebiotic strategy rebuilds the population. 4-month course, then reassess.
Sub-Grades
Brand
9.3
Bioavail
8.2
Evidence
6.2
Relevance
8.8
Brand Quality Assessment
CoreBiome® tributyrin, odor-minimized. Human RCT base thinner than the underlying butyrate biology would suggest.
B+
MegaPre® (Capsules)
Microbiome Labs · Manual Order · 6 capsules/day (full dose) · $60.29/mo
Overall
Grade
Grade
Why You're Taking It
Primary: Multi-fiber blend (FOS/XOS/GOS) formulated to feed Akkermansia, F. prausnitzii, and Bifidobacterium simultaneously — a distinct substrate class from PHGG, so not part of the FiberMend/Sunfiber overlap.
Reached full 6-capsule dose Jul 29, well tolerated.
Reached full 6-capsule dose Jul 29, well tolerated.
Sub-Grades
Brand
8.8
Bioavail
8.5
Evidence
6.5
Relevance
9.0
Brand Quality Assessment
Microbiome Labs practitioner-channel brand, GMP-manufactured. Capsule format costs roughly half of the powder format at full dose ($60.29/mo vs $120.56/mo).
🆕 Recommended Additions — August 2026
One item is indicated by the Jul 27 panel (Zinc, below, proposed but not yet ordered). Separately, one item has already been ordered as of Aug 16 — Mitopure/Urolithin A, graded above with the other active supplements, not listed here since it's no longer proposed.
A
Zinc (standalone) PROPOSED — NOT YET ORDERED
Suggested: Thorne Zinc Bisglycinate 15 mg or Pure Encapsulations Zinc 30 · ~$12–16/mo
Proposed
Grade
Grade
Why Add It Now
Serum zinc declined across five draws (74→72→69→70→63 mcg/dL) — in range but sliding, with thyroid-cofactor (T4→T3 deiodinase) and testosterone implications. Copper is the real risk at sustained doses above ~25-30mg — add copper + ceruloplasmin to the next panel if this is started.
Proposed Protocol
15-30mg elemental/day, bisglycinate or picolinate, with food, separated 2+ hours from magnesium.
📊 Summary Scorecard
| Rank | Supplement | Grade | Brand | Bioavail | Evidence | Relevance | Monthly | Verdict |
|---|---|---|---|---|---|---|---|---|
| 1 | Creatine | A+ | 9.5 | 9.5 | 9.9 | 9.6 | $12.75 | Best value in stack |
| 2 | Methyl-Guard Plus | A+ | 9.7 | 9.8 | 9.2 | 10.0 | $56.69 | Genetically essential |
| 3 | Super EPA Pro | A+ | 9.7 | 9.2 | 9.8 | 10.0 | $84.59 | EPA-dominant · take with fat |
| 4 | Red Yeast Rice | A | 9.5 | 8.8 | 9.2 | 9.7 | $12.82 | ✅ Broke the LDL plateau |
| 5 | Vitamin D3 5000 + K | A | 9.2 | 9.0 | 9.5 | 9.5 | $13.05 | Correction held — 62 ng/mL |
| 6 | Berberine | A | 9.5 | 8.5 | 9.5 | 9.4 | $40.49 | Glucose→lipids; may own the TG signal |
| 7 | Basic Nutrients 2/Day | A | 9.7 | 9.3 | 8.0 | 8.4 | $62.09 | Zinc coverage insufficient |
| 8 | LMNT Electrolytes | A | 9.0 | 9.2 | 8.5 | 9.3 | $39.00 | Clean formula, keto-optimized |
| 9 | FiberMend | A | 9.5 | 8.8 | 9.0 | 9.0 | $41.39 | Gut + lipid support |
| 10 | Magnesium Glycinate | A | 9.2 | 9.0 | 9.0 | 9.5 | $15.30 | COMT cofactor |
| 11 | Seed DS-01 Daily Synbiotic | A | 9.2 | 9.0 | 8.2 | 8.8 | $53.99 | Premium probiotic |
| 12 | NeuroCalm | A | 9.3 | 8.5 | 7.8 | 9.2 | $53.99 | COMT phenotype match |
| 13 | Lion's Mane | B+ | 9.0 | 8.5 | 6.8 | 8.0 | $34.98 | Good — emerging evidence |
| 14 | BPC-157 Prime w/CurcuPrime DISCONTINUED | B+ | 8.0 | 7.2 | 5.8 | 8.5 | $35.00 | Discontinued Aug 17 — see ProHealth below |
| 15 | Pure BPC-157 NEW AUG 18 | B+ | 8.3 | 7.4 | 5.8 | 8.2 | $59.98 | Starts Aug 18 — same mechanism, single-ingredient |
| 16 | Super Ubiquinol CoQ10 with PQQ | A | 9.2 | 9.4 | 9.2 | 9.5 | $30.38 | Kaneka™ · Replaced MitoActive |
| 17 | PQQ Caps 10 mg | A- | 9.2 | 8.5 | 7.8 | 9.0 | $6.75 | Completes 20 mg PQQ dose |
| 18 | Cellular Longevity PRO — Mitopure (Urolithin A) 1000mg NEW AUG 16 | A | 9.5 | 8.8 | 7.4 | 8.2 | ~$110.00 | Proactive — mitophagy, 3rd mito lever |
| 19 | Akkermansia 500 PRO | A | 8.8 | 8.0 | 7.8 | 9.8 | $62.99 | Phase 4 — confirmed-zero repletion |
| 20 | Sunfiber® (PHGG) | A | 8.5 | 9.0 | 8.8 | 9.6 | $32.22 | Phase 4 — F. prausnitzii substrate |
| 21 | Tri-Butyrin Supreme | B+ | 9.3 | 8.2 | 6.2 | 8.8 | $44.09 | Phase 4 — butyrate bridge, 4mo course |
| 22 | MegaPre® (Capsules) | B+ | 8.8 | 8.5 | 6.5 | 9.0 | $60.29 | Phase 4 — full dose since Jul 29 |
| PRIOR STACK SUBTOTAL (20 supplements, Aug 2) | $792.85 | per month | ||||||
| + MITOPURE / UROLITHIN A (new, Aug 16, estimate) | ~$110.00 | per month | ||||||
| − BPC-157 SWITCH: Apeiron discontinued (Aug 17) | −$35.00 | per month | ||||||
| + BPC-157 SWITCH: ProHealth Pure BPC-157 (Aug 18) | +$59.98 | per month | ||||||
| NEW TOTAL MONTHLY COST (21 supplements) | ~$927.83 | per month, ~Aug 18+ | ||||||
Mitopure pricing is a planning-level estimate per the Fullscript buying guide ($90-140/mo range depending on list vs. subscription pricing) — confirm the actual charged price in your Fullscript account. ProHealth Pure BPC-157 pricing ($119.95 for a 60-capsule/500mcg bottle, prohealth.com list price) is amortized the same way the outgoing Apeiron price was — as if taken continuously at 1 cap/day (60 caps ÷ 30 days ≈ 2 months' supply, $119.95 ÷ 2 ≈ $59.98/mo) — even though actual spend is lower in practice once 4-on/2-off cycling is factored in, matching how the Apeiron $35.00/mo figure was always presented. All other figures carried forward unchanged from the Aug 2, 2026 revision. See supplement-pricing-report.html for the full itemized breakdown once updated.
🕐 Daily Dosing Schedule
7:30 AM
7
caps + softgel (incl. Mitopure)
11:00 AM
20+
caps + 4 powders
9:00 PM
4
caps + tabs
DAILY TOTAL
31+
caps/tabs + 4 powders (as of Aug 16)
⚡ Bottom Line Assessment
Overall stack grade: A- (unchanged this revision — the BPC-157 switch is a lateral product move, not a quality or mechanism change, and Mitopure's Aug 16 addition remains evidence-consistent with the rest of the mitochondrial/energy system).
Aug 17, 2026 update — BPC-157 product switch. Apeiron Elements BPC-157 Prime w/CurcuPrime is discontinued after Aug 17; ProHealth Longevity's Pure BPC-157 (500 mcg, single-ingredient, Triple Lab Tested) takes its place starting Aug 18, on the same 4-on/2-off cycling schedule and 1 cap/day dose. Grade holds at B+ — brand quality is comparable, evidence depth is identical (still no large human RCTs for oral BPC-157), and the one real trade-off is the loss of the CurcuPrime curcumin co-formulation, nudging Relevance down slightly (8.5→8.2). Net stack cost moves from $35.00/mo to $59.98/mo for this slot (+$24.98/mo) — see the Summary Scorecard footer for the updated total.
Aug 16, 2026 update: Timeline Cellular Longevity PRO (Mitopure/Urolithin A 1000mg) added — the 21st active supplement. Unlike almost everything else in this stack, this was not triggered by a lab flag; it's a proactive longevity addition on the strength of two human RCTs using this exact branded ingredient (2022 muscle/dose-response trial, 2025 immune-aging trial). It joins CoQ10+PQQ as a third, mechanistically distinct mitochondrial lever — PQQ signals new mitochondria, CoQ10 fuels the electron transport chain, Urolithin A clears the damaged ones via mitophagy. Graded A (Brand 9.5, Bioavailability 8.8, Evidence 7.4, Relevance 8.2) — the honest evidence caveat is that this is a two-trial base for a novel compound, not the decades-deep literature behind creatine or omega-3s. Sourced through Fullscript specifically as Timeline's own Mitopure-branded product, because generic "urolithin A" listings have been shown (by Timeline's own 2023 testing) to sometimes contain none of the labeled compound at all. Taken fasted at 7:30 AM — its absorption, unlike Super EPA Pro's, is not meaningfully fat-dependent.
New total stack cost: ~$927.83/mo (up from ~$902.85 as of Aug 16, and $792.85 on Aug 2), 31+ caps/tabs plus 4 powders daily. No removals from the active count — the BPC-157 slot is a straight swap, not an addition, and every item, including Mitopure, has a defensible rationale tied to genetics, a specific lab finding, or (in Mitopure's case) a specific, well-matched trial dose.
Everything else in this assessment — the triglyceride/NMR retest as the single highest-priority action, the zinc proposal, the berberine cycling caveat — carries forward unchanged from the Aug 2, 2026 revision. See therapeutic-logic-report.html for the full systems-level view and Supplement_Stack_Timing_Jul2026.html for the day-by-day schedule.
Aug 17, 2026 update — BPC-157 product switch. Apeiron Elements BPC-157 Prime w/CurcuPrime is discontinued after Aug 17; ProHealth Longevity's Pure BPC-157 (500 mcg, single-ingredient, Triple Lab Tested) takes its place starting Aug 18, on the same 4-on/2-off cycling schedule and 1 cap/day dose. Grade holds at B+ — brand quality is comparable, evidence depth is identical (still no large human RCTs for oral BPC-157), and the one real trade-off is the loss of the CurcuPrime curcumin co-formulation, nudging Relevance down slightly (8.5→8.2). Net stack cost moves from $35.00/mo to $59.98/mo for this slot (+$24.98/mo) — see the Summary Scorecard footer for the updated total.
Aug 16, 2026 update: Timeline Cellular Longevity PRO (Mitopure/Urolithin A 1000mg) added — the 21st active supplement. Unlike almost everything else in this stack, this was not triggered by a lab flag; it's a proactive longevity addition on the strength of two human RCTs using this exact branded ingredient (2022 muscle/dose-response trial, 2025 immune-aging trial). It joins CoQ10+PQQ as a third, mechanistically distinct mitochondrial lever — PQQ signals new mitochondria, CoQ10 fuels the electron transport chain, Urolithin A clears the damaged ones via mitophagy. Graded A (Brand 9.5, Bioavailability 8.8, Evidence 7.4, Relevance 8.2) — the honest evidence caveat is that this is a two-trial base for a novel compound, not the decades-deep literature behind creatine or omega-3s. Sourced through Fullscript specifically as Timeline's own Mitopure-branded product, because generic "urolithin A" listings have been shown (by Timeline's own 2023 testing) to sometimes contain none of the labeled compound at all. Taken fasted at 7:30 AM — its absorption, unlike Super EPA Pro's, is not meaningfully fat-dependent.
New total stack cost: ~$927.83/mo (up from ~$902.85 as of Aug 16, and $792.85 on Aug 2), 31+ caps/tabs plus 4 powders daily. No removals from the active count — the BPC-157 slot is a straight swap, not an addition, and every item, including Mitopure, has a defensible rationale tied to genetics, a specific lab finding, or (in Mitopure's case) a specific, well-matched trial dose.
Everything else in this assessment — the triglyceride/NMR retest as the single highest-priority action, the zinc proposal, the berberine cycling caveat — carries forward unchanged from the Aug 2, 2026 revision. See therapeutic-logic-report.html for the full systems-level view and Supplement_Stack_Timing_Jul2026.html for the day-by-day schedule.